Nicotine facilitates VSMC dysfunction through a miR-200b/RhoGDIA/cytoskeleton module

Area of Science:

• Vascular Biology
• Molecular Medicine
• Epigenetics

Background:

• Nicotine exposure is linked to vascular smooth muscle cell (VSMC) dysfunction, affecting migration and proliferation.
• Cytoskeletal proteins and RhoGDIA, a Rho GTPase pathway regulator, are implicated in nicotine-induced VSMC abnormalities.

Purpose of the Study:

• To elucidate the molecular mechanisms by which nicotine induces VSMC dysfunction.
• To identify key signaling pathways and regulatory elements involved in nicotine's effects on VSMCs.
• To investigate the role of microRNA-200b (miR-200b) and epigenetic modifications in nicotine-induced VSMC behavior.

Main Methods:

• Investigated nicotine's effects on VSMC Rho GTPase pathway activation, cytoskeletal protein synthesis, and RhoGDIA expression (mRNA and protein).
• Utilized dual luciferase reporter assays to identify miR-200b as a direct target of RhoGDIA.
• Employed miR-200b inhibitors in cultured VSMCs and analyzed miR-200b promoter methylation status.

Main Results:

• Nicotine activates the Rho GTPase pathway and downstream signaling (MYPT1, PAK1, PI3K/AKT), inducing cytoskeletal protein synthesis in VSMCs.
• Nicotine treatment decreases RhoGDIA protein levels despite increased mRNA, indicating post-translational regulation.
• miR-200b directly targets RhoGDIA, and its inhibition attenuates nicotine-induced VSMC proliferation and migration.
• Nicotine-induced miR-200b upregulation is mediated by hypomethylation in its CpG island shore region.

Conclusions:

• Nicotine promotes VSMC dysfunction via a miR-200b/RhoGDIA/cytoskeleton signaling axis.
• Epigenetic modifications, specifically hypomethylation of the miR-200b promoter, are crucial in nicotine-induced VSMC pathology.
• Targeting the miR-200b/RhoGDIA pathway may offer therapeutic strategies for nicotine-related vascular diseases.